[go: up one dir, main page]

NO20064621L - Ekspresjon av lipoproteiner. - Google Patents

Ekspresjon av lipoproteiner.

Info

Publication number
NO20064621L
NO20064621L NO20064621A NO20064621A NO20064621L NO 20064621 L NO20064621 L NO 20064621L NO 20064621 A NO20064621 A NO 20064621A NO 20064621 A NO20064621 A NO 20064621A NO 20064621 L NO20064621 L NO 20064621L
Authority
NO
Norway
Prior art keywords
protein
leader sequence
lipidated
heterologous
expression
Prior art date
Application number
NO20064621A
Other languages
English (en)
Inventor
Lorne Franklin Erdile
Robert S Becker
Robert C Huebner
Donald J Warakomski
Maryann B Gray
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20064621L publication Critical patent/NO20064621L/no
Application filed by Connaught Lab filed Critical Connaught Lab

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det er beskrevet og krevd heterologe lipiderte proteiner som er fremstilt ved rekombinante fremgangsmåter. Ekspresjonssystemet kan være E. coli. Det heterologe lipiderte protein har en ledersekvens som ikke naturlig forekommer med proteindelen av det lipiderte protein. Det lipiderte protein kan ha ledersekvensen for Borrelia-OspA. Proteindelen kan være OspC, PspA, UreA, UreB eller et fragment derav. Fremgangsmåte og sammensetninger for fremstilling av og anvendelse av proteinene er også beskrevet og krevd.
NO20064621A 1995-06-07 2006-10-09 Ekspresjon av lipoproteiner. NO20064621L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48637395A 1995-06-07 1995-06-07
US47578195A 1995-06-07 1995-06-07
PCT/IB1996/000633 WO1996040718A1 (en) 1995-06-07 1996-06-05 Expression of lipoproteins

Publications (1)

Publication Number Publication Date
NO20064621L true NO20064621L (no) 1998-01-30

Family

ID=27044930

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19975619A NO324089B1 (no) 1995-06-07 1997-12-04 Hybrid nukleinsyremolekyl for fremstilling av lipiderte rekombinante proteiner fra Borrelia-arter.
NO20064621A NO20064621L (no) 1995-06-07 2006-10-09 Ekspresjon av lipoproteiner.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19975619A NO324089B1 (no) 1995-06-07 1997-12-04 Hybrid nukleinsyremolekyl for fremstilling av lipiderte rekombinante proteiner fra Borrelia-arter.

Country Status (13)

Country Link
EP (2) EP0832093B1 (no)
JP (1) JP4091112B2 (no)
AT (1) ATE339436T1 (no)
AU (1) AU721954B2 (no)
CA (2) CA2223300C (no)
DE (1) DE69636544T2 (no)
DK (1) DK0832093T3 (no)
ES (1) ES2271954T3 (no)
FI (1) FI974422L (no)
IL (1) IL118578A (no)
NO (2) NO324089B1 (no)
PT (1) PT832093E (no)
WO (1) WO1996040718A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
ES2334185T3 (es) * 1998-02-03 2010-03-05 Center For Disease Control And Prevention Proteina psaa lipidada recombinante, procedimientos de preparacion y uilizacion.
EP1261723B1 (en) * 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1812058B1 (en) 2004-10-25 2012-06-13 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
JP5219808B2 (ja) 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
KR102899781B1 (ko) 2006-01-19 2025-12-12 마리 케이 인코포레이티드 카카두 플럼 추출물 또는 아카이 베리 추출물을 포함하는 조성물
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2421885T3 (es) 2008-12-12 2013-09-06 Euroimmun Medizinische Labordiagnostika Ag Polipéptidos y procedimiento para la detección específica de anticuerpos en pacientes con una infección por Borrelia
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
MX2012002424A (es) 2009-08-28 2012-06-27 Mary Kay Inc Formulaciones para el cuidado de la piel.
DK3246044T4 (da) 2010-08-23 2024-05-21 Wyeth Llc Stabile formuleringer af Neisseria-meningitidis-RLP2086-antigener
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
SG47447A1 (en) * 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
DE69226167T2 (de) * 1991-02-15 1998-11-12 The Uab Research Foundation, Birmingham, Alabama Strukturgen von pneumokokken-protein
DE69232956T2 (de) * 1991-10-22 2003-10-02 Symbicom Ab, Moelndal Verbesserungen der diagnose und der prophylaxe von borrelia burgdorferi
AU5958594A (en) * 1992-12-24 1994-07-19 Med Immune, Inc. Method of protection against (streptococcus pneumoniae) with transformed mycobacteria

Also Published As

Publication number Publication date
NO975619L (no) 1998-01-30
ES2271954T3 (es) 2007-04-16
FI974422A0 (fi) 1997-12-05
NO324089B1 (no) 2007-08-13
FI974422A7 (fi) 1998-02-04
EP0832093A1 (en) 1998-04-01
AU6134396A (en) 1996-12-30
CA2704354A1 (en) 1996-12-19
FI974422L (fi) 1998-02-04
AU721954B2 (en) 2000-07-20
DE69636544T2 (de) 2007-06-06
IL118578A0 (en) 1996-10-16
DK0832093T3 (da) 2007-01-08
JPH11514841A (ja) 1999-12-21
JP4091112B2 (ja) 2008-05-28
IL118578A (en) 2006-12-31
NO975619D0 (no) 1997-12-04
ATE339436T1 (de) 2006-10-15
EP0832093B1 (en) 2006-09-13
EP0832093A4 (en) 2001-01-03
PT832093E (pt) 2006-12-29
EP1741718A2 (en) 2007-01-10
CA2223300C (en) 2010-07-27
DE69636544D1 (de) 2006-10-26
CA2223300A1 (en) 1996-12-19
WO1996040718A1 (en) 1996-12-19
EP1741718A3 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
NO20064621L (no) Ekspresjon av lipoproteiner.
FI946199L (fi) Menetelmä rekonstituoidun lipoproteiinin valmistamiseksi
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
BR9713521A (no)
DK322188A (da) Fremgangsmaade til fremstilling af protein
BR9906927A (pt) Proteìnas de neisseria meningitidis
NZ508366A (en) Neisseria meningitidis antigens and compositions
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
DK0729951T3 (da) Naphthylforbindelser, mellemprodukter, præparater og fremgangsmåder
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE69632827D1 (de) Materialen und methoden im zusammenhang mit bindung und präsentation von substanzen auf zelloberflächen
HUP9902457A2 (hu) Pneumococcus felületi fehérjéket tartalmazó oltóanyag-készítmények
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
DK0781341T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler
DE69128039D1 (de) Allergene aus roggenspreupollen
SE9602822D0 (sv) New receptor
FI965228L (fi) Menetelmä 1,4-butaanidiolin valmistamiseksi
FR2692349B1 (fr) Gyromètre à poutre vibrante, à excitation piézo-électrique.
FI940846L (fi) Menetelmä heraproteiinien eristämiseksi
ITMI942238A0 (it) Anticorpi naturali contro proteine allogeniche e xenogeniche e me- todi per la loro determinazione
FI870501L (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application